Dry eye disease is a common problem, and Sight Sciences Inc., of Menlo Park, Calif., is looking to help those who suffer from the condition. Now, the company has seen the presentation of positive clinical data from the multicenter OLYMPIA study of Tearcare, which the company has heralded as the first wearable and intelligent eyelid technology for dry eye treatment.

BOGOTA – Mexican home appliances manufacturer Mabe Sa De Cv, from Mexico City, became a new member of the med-tech sector after taking the leap forward and joining the scores of companies around the world shifting their traditional manufacturing lines to develop med-tech products to fight COVID-19.

Quanterix Corp., of Billerica, Mass., reported that researchers have developed a COVID-19 antibody test with 1,000 times the sensitivity of current tests using its Simoa bead-based immunoassay platform.

ERTH, Australia – A recent study conducted at the University of Western Australia (UWA) Centre for Sleep Science shows that facial features analyzed from 3D photographs could predict the likelihood of having obstructive sleep apnea.

LONDON – Support is growing for human challenge trials in COVID-19 to be approved in order to speed up development of effective vaccines against the pandemic infection.

Boston Scientific Corp. reported positive results for its Emblem subcutaneous implantable defibrillator (S-ICD) system and next-generation Watchman Flx left atrial appendage closure (LAAC) device at the Heart Rhythm Society scientific sessions, which were online only this year due to the COVID-19 pandemic.

LONDON – A new technique for analyzing solid tumor DNA has been shown to significantly improve scoring of mutation burden, making it possible to identify patients who will respond to immunotherapy.

Wearables giant Fitbit Inc. has kicked off its first large-scale, virtual study to evaluate how well its wrist-worn technology can spot episodes of irregular heart rhythm that might indicate atrial fibrillation (AF). The study, part of a broader plan to equip Fitbit devices with new tools to speed the detection of a range of conditions, is open to people in the U.S. ages 22 and older who own a Fitbit that tracks heart rate.

Stem cells haven’t exactly panned out as hoped when it comes to approved therapeutics. There are only a couple that have received a nod from the FDA in very specific indications. But the ongoing COVID-19 pandemic could push stem cells back into the limelight and more firmly establish them as therapeutically relevant.

Pasadena, Calif.-based Circularity Healthcare LLC has initiated a clinical trial to evaluate its transdermal microcirculation device in COVID-19 patients with underlying health conditions. The aim is to see if use of the noninvasive deoxyhemoglobin vasodilator (from which the product derives its name) improves outcomes in patients suffering from coronavirus-related complications.